- Hologic press release ( NASDAQ: HOLX ): Q1 Non-GAAP EPS of $1.07 beats by $0.14 .
- Revenue of $1.07B (-27.2% Y/Y) beats by $60M .
- Diagnostics revenue decreased (41.2%), or (39.4%) in constant currency, primarily driven by lower sales of COVID-19 assays compared to the prior year period.
- Cash flow from operations remained very strong in the first quarter at $253.4 million. In addition, the Company repurchased 1.5 million shares of its stock for $100 million in the quarter.
For further details see:
Hologic Non-GAAP EPS of $1.07 beats by $0.14, revenue of $1.07B beats by $60M